scholarly journals BRCA1 Gene Mutation Negative

2020 ◽  
Author(s):  
Keyword(s):  
Gene Mutation ◽  
Brca1 Gene ◽  
Brca1 Gene Mutation

Autoantibodies directed to centromere protein F in a patient with BRCA1 gene mutation

Pathology ◽  
2015 ◽  
Vol 47 ◽  
pp. S94
Author(s):  
Fiona Moghaddas ◽  
Fredrick Joshua ◽  
Bobbie Taylor ◽  
Marv Fritzler ◽  
Ban Hock Toh
Keyword(s):  
Gene Mutation ◽  
Brca1 Gene ◽  
Brca1 Gene Mutation ◽  
Centromere Protein ◽  
Protein F

Genetic testing and interpretive complexity: a BRCA1 gene mutation example

2014 ◽  
Vol 185 (4) ◽  
pp. 955-957
Author(s):  
D. S. Gogarty ◽  
M. P. Farrell ◽  
D. J. Gallagher
Keyword(s):  
Genetic Testing ◽  
Gene Mutation ◽  
Brca1 Gene ◽  
Brca1 Gene Mutation

scholarly journals HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases

2017 ◽  
Vol 2017 ◽  
pp. 1-13 ◽  
Author(s):  
Anita Chudecka-Głaz ◽  
Aneta Cymbaluk-Płoska ◽  
Aleksandra Strojna ◽  
Janusz Menkiszak
Keyword(s):  
Endometrial Cancer ◽  
Gene Mutation ◽  
Uterine Cancer ◽  
Brca1 Gene ◽  
Prophylactic Surgery ◽  
Ca 125 ◽  
Fallopian Tube Cancer ◽  
Brca1 Gene Mutation ◽  
Gynecological Diseases ◽  
Diagnostic Usefulness

Objective. We assess the behavior of serum concentrations of HE4 marker in female carriers of BRCA1 and assess the diagnostic usefulness of HE4 in ovarian and endometrial cancer.Methods. A total of 619 women with BRCA1 gene mutation, ovarian, endometrial, metastatic, other gynecological cancers, or benign gynecological diseases were included. Intergroup comparative analyses were carried out, the BRCA1 gene carriers subgroup was subjected to detailed analysis, and ROC curves were determined for the assessment of diagnostic usefulness of HE4 in ovarian and endometrial cancer.Results. Statistically lower serum HE4 and CA 125 levels were observed in BRCA1 gene mutation premenopausal carriers. Occult ovarian/fallopian tube cancer was found 3.6%. Each of those patients was characterized by slightly elevated levels of either CA 125 (63.9 and 39.4 U/mL) or HE4 (79 pmol/L). The ROC-AUC curves were 0.892 and 0.894 for diagnostic usefulness of ovarian cancer and 0.865 for differentiation of endometrial cancer from endometrial polyps.Conclusions. Patients with BRCA1 gene mutations have relatively low serum HE4 levels. Even the slightest elevation in HE4 or CA 125 levels in female BRCA1 carriers undergoing prophylactic surgery should significantly increase oncological alertness. The HE4 marker is valuable in ovarian and uterine cancer diagnosis.

Interest in a Support Group Among Individuals Tested for a BRCA1 Gene Mutation

2000 ◽  
Vol 18 (4) ◽  
pp. 15-37 ◽  
Author(s):  
Heidi A. Hamann ◽  
Robert T. Croyle ◽  
Ken R. Smith ◽  
Barbara N. M. Quan ◽  
Kathryn L. McCance ◽  
...  
Keyword(s):  
Gene Mutation ◽  
Support Group ◽  
Brca1 Gene ◽  
Brca1 Gene Mutation

scholarly journals Data mining approach to predict BRCA1 gene mutation

2013 ◽  
Vol 1 (2) ◽  
Author(s):  
Olegas Niakšu ◽  
Jurgita Gedminaitė ◽  
Olga Kurasova
Keyword(s):  
Data Mining ◽  
Gene Mutation ◽  
Brca1 Gene ◽  
Brca1 Gene Mutation ◽  
Data Mining Approach
Sign in / Sign up

Export Citation Format

Share Document